Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianping Weng

Showing results (221-230 of 295) with videos related to

Pageof 30
Sort By:
Diabetologia|May 23, 2021
HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetesZiyu Jiang, Wenqian Ren, Hua Liang, et al.
Communications Medicine|February 22, 2023
Higher mitochondrial DNA copy number is associated with metformin-induced weight lossJing Wang, Hua Liang, Rong Huang, et al.
Diabetes, Obesity & Metabolism|January 21, 2017
Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in ChinaLinong Ji, Puhong Zhang, Dongshan Zhu, et al.
Diabetes Technology & Therapeutics|July 15, 2015
Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline CharacteristicsLinong Ji, Puhong Zhang, Jianping Weng, et al.
Signal Transduction and Targeted Therapy|November 13, 2025
Catheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm studyZhi Wang, Tao Pan, Weifu Lv, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialJianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Pharmacological Reviews|June 5, 2021
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to PharmacotherapiesSuowen Xu, Iqra Ilyas, Peter J Little, et al.
Science Bulletin|April 17, 2026
Hepatic IFRD1 suppresses metabolic dysfunction-associated fatty liver disease via GLUD1/α-KG axisMengya Geng, Fanzheng Meng, Hairui Li, et al.
Journal of Diabetes|October 29, 2014
Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherenceYuying Zhang, Rose Zw Ting, Wenying Yang, et al.
Eclinicalmedicine|February 22, 2021
Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysisCarlos K H Wong, Eric Y F Wan, Sihui Luo, et al.
Pageof 30

Showing results (221-230 of 295) with videos related to

Sort By:
Pageof 30
Diabetologia|May 23, 2021
HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetesZiyu Jiang, Wenqian Ren, Hua Liang, et al.
Communications Medicine|February 22, 2023
Higher mitochondrial DNA copy number is associated with metformin-induced weight lossJing Wang, Hua Liang, Rong Huang, et al.
Diabetes, Obesity & Metabolism|January 21, 2017
Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in ChinaLinong Ji, Puhong Zhang, Dongshan Zhu, et al.
Diabetes Technology & Therapeutics|July 15, 2015
Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline CharacteristicsLinong Ji, Puhong Zhang, Jianping Weng, et al.
Signal Transduction and Targeted Therapy|November 13, 2025
Catheter-based endovascular celiac and hepatic denervation for type 2 diabetes: a multicenter, open-label, single-arm studyZhi Wang, Tao Pan, Weifu Lv, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialJianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Pharmacological Reviews|June 5, 2021
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to PharmacotherapiesSuowen Xu, Iqra Ilyas, Peter J Little, et al.
Science Bulletin|April 17, 2026
Hepatic IFRD1 suppresses metabolic dysfunction-associated fatty liver disease via GLUD1/α-KG axisMengya Geng, Fanzheng Meng, Hairui Li, et al.
Journal of Diabetes|October 29, 2014
Depression in Chinese patients with type 2 diabetes: associations with hyperglycemia, hypoglycemia, and poor treatment adherenceYuying Zhang, Rose Zw Ting, Wenying Yang, et al.
Eclinicalmedicine|February 22, 2021
Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysisCarlos K H Wong, Eric Y F Wan, Sihui Luo, et al.
Pageof 30